

PASCO Ventures LLC

Paul A. Stewart, Certified Licensing Professional
Managing Director


✉ pas@pascoventures.com

☎ 317-590-1099

10719 Snowblossom Way
Highlands Ranch, CO 80126-5753 USA

April 2025

RE: EXCLUSIVE LICENSING OPPORTUNITY FOR NORKETOTIFEN (“NK”) FOR HUMAN DERMAL AND PULMONARY INDICATIONS – FROM BRIDGE PHARMA, INC.



Norketotifen (“NK” – click on hyperlink for *PubChem* info)

Founded in 1996, Florida-based Bridge Pharma, Inc. (“**Bridge**”) has operated for several years in ‘stealth’ mode to develop NK for various human Dermal and Pulmonary indications. Fortunately, Bridge has benefited from the generous financial support of a billionaire angel investor; combined with Bridge’s capital resources, this billionaire’s repeated investments over the years have allowed Bridge to focus its energies on the successful completion of Phase-1 and Phase-2a human studies of NK rather than fundraising. At least 4 US Patents (and foreign counterparts) are filed or issued.

NK has successfully just finished Phase-2a human clinical trials. Once approved by the FDA, NK will be the world’s first oral, daily, non-immunosuppressive, non-sedating, non-steroidal drug for Atopic Dermatitis and other maladies that afflict millions of patients.

Fortunately, NK is a small molecule, and it will be much lower in cost than any of today’s biologics like DUPIXENT® with annual per-patient cost of up to \$25,000 or more per year. With today’s heightened sensitivity about the cost of pharmaceuticals, NK will be a welcome addition to the clinical armamentarium to treat various Dermal and Pulmonary diseases.

Sadly, Bridge’s iconic founder, **Dr. Gunnar Aberg**, died at the age of 88 on November 10, 2024, surrounded by his loving wife Laurie and his family. Just a few weeks after Gunnar’s death, positive results from the just-completed Phase-2a human study of NK were received. Gunnar’s family has now decided that it would be best to find a corporate pharma partner to advance NK from this point forward, and they have asked PASCO Ventures to assist them with this licensing process.

If you or your firm (or someone you know) has an interest in licensing NK, please contact me via email at pas@pascoventures.com, or by phone at +1-317-590-1099. An Investigator’s Brochure and additional confidential information is available to interested parties. Thank you.

On behalf of Bridge Pharma, Inc.,

PASCO Ventures LLC
by Paul A. Stewart, Certified Licensing Professional, Managing Director

CCs to Laurie and Peter Aberg, co-CEOs of Bridge Pharma, Inc.